BiotechTube

Rapid Acting insulin with pre-treatment of rHuPH20

ApprovedCompleted
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Type 1 Diabetes Mellitus

Conditions

Type 1 Diabetes Mellitus

Trial Timeline

Oct 3, 2013 → Feb 27, 2014

NCT ID
NCT03662334

About Rapid Acting insulin with pre-treatment of rHuPH20

Rapid Acting insulin with pre-treatment of rHuPH20 is a approved stage product being developed by Halozyme Therapeutics for Type 1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT03662334. Target conditions include Type 1 Diabetes Mellitus.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT03662334ApprovedCompleted

Competing Products

20 competing products in Type 1 Diabetes Mellitus

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Halozyme Therapeutics

Commercial Hylenex® recombinant (hyaluronidase human injection) + Precommercial Hylenex recombinant (hyaluronidase human injection) + Insulin lispro + Insulin aspart + Insulin glulisineApproved
82
HylenexApproved
82
large protein moleculeApproved
82
Sham Injection + Recombinant human hyaluronidase PH20 + Insulin aspart + Insulin lisproApproved
82
HylenexPhase 3
74